263 related articles for article (PubMed ID: 11389123)
1. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
Munckhof WJ; Giles C; Turnidge JD
J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
[TBL] [Abstract][Full Text] [Related]
2. The post-antibiotic effects of linezolid against Gram-positive pathogens.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Aydemir S
Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
Sweeney MT; Zurenko GE
Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
Stefani S; Mezzatesta ML; Tempera G; Debbra E; Schito AM; Nicoletti G; Marchére A
Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
[TBL] [Abstract][Full Text] [Related]
7. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.
Bell JM; Turnidge JD; Ballow CH; Jones RN;
J Antimicrob Chemother; 2003 Feb; 51(2):339-45. PubMed ID: 12562700
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility testing of linezolid by two standard methods.
Hamilton-Miller JM; Shah S
Eur J Clin Microbiol Infect Dis; 1999 Mar; 18(3):225-7. PubMed ID: 10357061
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
[TBL] [Abstract][Full Text] [Related]
11. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
Ho PL; Ng TK; Yung RW; Que TL; Yip EK; Tse CW; Yuen KY
J Antimicrob Chemother; 2001 Oct; 48(4):590-2. PubMed ID: 11581246
[No Abstract] [Full Text] [Related]
12. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
Livermore DM; Warner M; Mushtaq S; North S; Woodford N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
Henwood CJ; Livermore DM; Johnson AP; James D; Warner M; Gardiner A
J Antimicrob Chemother; 2000 Dec; 46(6):931-40. PubMed ID: 11102412
[TBL] [Abstract][Full Text] [Related]
15. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of linezolid against Gram-positive uropathogens of hospitalized patients with complicated urinary tract infections.
Onda H; Wagenlehner FM; Lehn N; Naber KG
Int J Antimicrob Agents; 2001 Sep; 18(3):263-6. PubMed ID: 11673040
[TBL] [Abstract][Full Text] [Related]
17. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
20. Action of linezolid or vancomycin on biofilms in ventriculoperitoneal shunts in vitro.
Bayston R; Ullas G; Ashraf W
Antimicrob Agents Chemother; 2012 Jun; 56(6):2842-5. PubMed ID: 22430965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
